You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 6,340,689


✉ Email this page to a colleague

« Back to Dashboard


Title: Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
Abstract:A method of treating an atypical upper respiratory pathogenic bacteria comprising administering a gemifloxacin compound is disclosed.
Inventor(s): Dubois; Jacques (Fleuramont, CA), St-Pierre; Claude (St-Elie d'Orford, CA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Filing Date:Sep 14, 1999
Application Number:09/395,851
Claims:1. A method for modulating metabolism of an atypical upper respiratory pathogexnic bacteria comprising the step of contacting atypical upper respiratory pathogenic bacteria with an antibacterially effective amount of a composition comprising a gemifloxacin compound, or an antibacterially effective derivative thereof, and wherein said atypical, upper respiratory pathogenic bacteria is selected from the group consisting of: a L. dumoffii strain, a L. longbeacheae strain, a L. micdadei strain, a L. oakridgensis strain, a L. feelei strain, a L. anisa strain, a L. sainthelensi strain, a L. bozemanii strain, a L. gormanii strain, a L. wadsworthii strain, and a L. jordanis strain.

2. The method of claim 1 wherein said modulating metabolism is inhibiting growth of said bacteria.

3. The method of claim 1 wherein said modulating metabolism is killing said bacteria.

4. The method of claim 1 wherein said contacting said bacteria comprises the further step of introducing said composition into a mammal.

5. A method of treating or preventing a bacterial infection by atypical upper respiratory pathogenic bacteria comprising the step of administering an antibacterially effective amount of a composition comprising a gemifloxacin compound, or an antibacterially effective derivative thereof, to a mammal suspected of having or being at risk of having an infection with atypical upper respiratory pathogenic bacteria, and wherein said atypical upper respiratory pathogenic bacteria is selected from the group consisting of: a L. dumoffii strain, a L. longbeacheae strain, a L. micdadei strain, a L. oakridgensis strain, a L. feelei strain, a L. anisa strain, a L. sainthelensi strain, a L. bozemanii strain, a L. gormanii strain, a L. wadsworthii strain, and a L. jordanis strain.

6. The method of claim 1 or 5 wherein said contacting is performed once daily.

7. The method according to claim 1 or 5 wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.

8. The method according to claim 7 wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.

9. The method according to claim 8 wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.